Literature DB >> 9076850

The pharmacological aspects of the treatment of acromegaly.

A Giustina1, G Zaltieri, F Negrini, W B Wehrenberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9076850     DOI: 10.1006/phrs.1996.0095

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


× No keyword cloud information.
  6 in total

Review 1.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

Review 2.  Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Authors:  Monica Gola; Mauro Doga; Stefania Bonadonna; Gherardo Mazziotti; Pier Paolo Vescovi; Andrea Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

3.  Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy.

Authors:  F Manelli; P Desenzani; E Boni; G Bugari; F Negrini; G Romanelli; V Grassi; A Giustina
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

4.  Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?

Authors:  E De Menis; G Tulipano; S Villa; D Billeci; C Bonfanti; P Pollara; P Pauletto; A Giustina
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 5.  Resistance to somatostatin analogs in acromegaly: an evolving concept?

Authors:  M Gola; S Bonadonna; G Mazziotti; G Amato; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

6.  Meta-analysis on the effects of octreotide on tumor mass in acromegaly.

Authors:  Andrea Giustina; Gherardo Mazziotti; Valter Torri; Maurizio Spinello; Irene Floriani; Shlomo Melmed
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.